
Nordic Nanovector announces the appointment of Joanna Horobin as Non-Executive Board Director
pharmafile | October 13, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Nordic Nanovector, appointment, norway
Nordic Nanovector announced on 12 October that Joanna Horobin was elected to its Board as non-executive director at the company’s interestingly named Extraordinary General Meeting (EGM), held in Oslo, Norway. Dr Horobin steps into the position vacated by Dr Renee P Tannenbaum, who stepped down from the board of directors for personal reasons.
Dr Horobin is currently senior vice president, chief medical officer and a member of the leadership team at Idera Pharmaceuticals. Her current role involves the development and regulatory strategy as well as the execution of the clinical trial programme for the company’s pipeline of novel oligonucleotides for the treatment of rare oncology and other indications.
Prior to this position, Horobin was CMO of Verastem, Inc. and CEO of Syndax Pharmaceuticals. Ms Horobin has also held several roles of at global pharmaceutical companies such as Rhône Poulenc Rorer (now Sanofi), where she led the global launch of Taxotere (docetaxel) in breast cancer and Campto/Camptosar (CPT11) for colorectal cancer. Ms Horobin also led a joint venture with Chugai to launch Granocyte (lenograstim) and held leadership roles in the approvals of several successful products.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






